Innovations in cancer diagnostics

Better understanding of the biology underlying patient tumors

bioTheranostics provides molecular diagnostic tests that improve the classification of cancer and support physicians in determining a more specific breast cancer prognosis or individual risk of recurrence for patients.

All tests are real time, RT-PCR based assays that are compatible with readily available, formalin-fixed paraffin embedded (FFPE) needle core biopsies, excisional biopsies, and/or surgical samples.

Molecular cancer classification that identifies primary site of origin

CancerTYPE ID^® is a molecular classification assay that measures and integrates the expression of 92 genes to distinguish up to 54 different tumor types. ^1,2

Molecular insights that improve breast cancer risk prognosis and management

Breast Cancer Index^SM, a combination of H/I^SM (HOXB13:IL17BR) and MGI^SM (Molecular Grade Index), refines and improves risk prognosis in patients with estrogen receptor-positive, lymph node-negative breast cancer. This test results in a more complete picture of prognostic information necessary for recurrence risk, therapeutic options such as endocrine therapy, and treatment decisions for each individual patient.

References:
1. Ma, et al. Molecular Classification of Human Cancers Using a 92-Gene Real Time Quantitative Polymerase Chain Reaction Assay. Archives of Pathology and Laboratory Medicine, 130: 465-473, 2006.
2. Data on file.  Technical Report 021510, bioTheranostics.